JUNE 3 JUN 3
2017
7:00 AM - 4:20 PM
SATURDAY SAT

Stanford’s 3rd Annual Mechanical Circulatory Support: Optimal Management and New Frontiers

LKSC - Stanford, CA

Registration is now closed

On-site registration will be available until full

A Continuing Medical Education Conference

Presented by the Department of Cardiothoracic Surgery and the Division of Cardiovascular Medicine at the Stanford University School of Medicine

Sponsored by the Stanford University  School of Medicine


Conference Team

CME Conference Coordinator
(650) 724-9549

Mailing List

New activities are added regularly.  Join our mailing list to receive notifications about activities of interest to you.

Statement of Need

This CME workshop seeks to improve the knowledge of cardiology physicians, cardiothoracic surgeons, nurses and nurse practitioners regarding appropriate options in mechanical circulatory support (MCS) for patients with end stage heart failure and management of these patients before and after receiving MCS. We will include review of clinical criteria to refer patients, different types of MCS and the scenarios for their use, strategies to support and manage patients prior to and post MCS, based on latest development in treatment.  We will employ didactic lectures, interactive cases, and small group discussions to improve learner’s knowledge of evidence based management of patients with end stage heart failure.

Target Audience

  • This is a regional program, designed for physicians, nurse practitioners, nurses, and allied health professionals who practice in the fields of:
    • Cardiology
    • Cardiothoracic Surgery
    • Internal Medicine

Learning Objectives

  • At the conclusion of this activity, learners will be able to:
    • Identify and implement clinical criteria to refer patients who may benefit from mechanical circulatory support at an optimal time to create better patient outcomes.
    • Identify appropriate patients for emergent mechanical circulatory support and select appropriate therapy options (ECMO, percutaneous pVAD, intra-aortic balloon pump). 
    • Optimally mange patients prior to MC by initiating inotropic therapy at the appropriate time and serially monitoring right ventricular and end organ function. 
    • Discuss the need and opportunities to build a MCS framework that includes appropriate infrastructure and personnel, and partnering with referring providers. 
    • Develop strategies to manage post MCS complications based on the latest development in treatment for patients with:
      • Gastrointestinal bleeding post LVAD
      • Arrhythmias post LVAD
      • Right ventricular failure post LVAD